August 2012
-
The US Department of Health and Human Services (HHS) has announced that its Biomedical Advanced Research and Development Authority (BARDA) has issued a $10.49 million task order to the Centers for Innovation in Advanced Development… Read more . . .
-
CRO Aptuit has acquired preclinical formulation specialist Kuecept Ltd, the company said. Both companies have extensive experience in respiratory drug delivery. Kuecept Founder and CEO Mark Saunders commented, “Since our inception in 2007, we have… Read more . . .
-
Grupo Ferrer will acquire inhaled drug developer Alexza Pharmaceuticals for $0.90 per share in a deal that is expected to be completed by mid-2016, the two companies have announced. In February 2016, Alexza announced that… Read more . . .
-
Submission for podium and poster presentations are due by July 29, 2016. Areas of particular interest for DDL27 include: • Inhalers – were they really meant for humans? • Beyond Asthma and COPD • 60… Read more . . .
-
Submit workshop proposals by June 16, 2016 at http://www.rddonline.com/rdd/workshop_reg.php?id=14&sid=6. Podium abstract submissions accepted until August 1, 2016 at http://www.rddonline.com/rdd/speaker_reg.php?id=14. Scientific poster abstract submissions will be due by January 6, 2017. Read more . . .
-
Marina Biotech will pay up to $95 million in milestone payments, plus a “mid-single digit” royalty, in addition to 53 million Marina common shares to acquire Turing Pharmaceutical’s intranasal ketamine program, including all existing product,… Read more . . .
-
Catalent Pharma Solutions. As a member of the inhalation development team, you will utilize your expertise to support the advancement of a variety of pulmonary dosage forms that include pMDIs, DPIs, nasal sprays and solutions/suspensions… Read more . . .
-
On the first morning of RDD 2016, Peter Byron welcomed over 600 OINDP specialists from approximately 30 different countries to this year’s meeting, which offered an optimistic vision of the future of inhaled and nasal… Read more . . .
-
An EMA Pharmacovigilance Risk Assessment Committee (PRAC) review of published data from controlled clinical trials, observational studies, and meta-analyses has concluded that all inhaled corticosteroid (ICS) products appear to carry a similar risk of pneumonia… Read more . . .
-
The FDA has approved Teva’s supplemental NDA for ProAir RespiClick albuterol breath-activated DPI for the treatment or asthma in children aged 4 to 11, the company has announced. The sNDA filing was accepted by the… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland